MicroRNA Temporal Detection for Left Ventricular Remodeling Assessment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack the ability to reliably measure specific temporal changes in microRNAs in patients following myocardial infarction, which are crucial for assessing left ventricular remodeling and cardiac health.
Innovation Solution
The method involves detecting specific microRNAs such as miR-1, miR-21, miR-29a, miR-133a, and miR-208 in body fluids like plasma at multiple time points post-myocardial infarction, using quantitative PCR and normalization to snRNA U6, to establish temporal patterns indicative of remodeling severity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If microRNA levels are measured in myocardial tissue, then regulatory role in myocardial growth and remodeling can be assessed, but invasive tissue sampling is required which increases patient risk and complexity
Solution Approach 1:
The patent uses body fluids (plasma, serum, urine, CSF) as intermediary substances to detect microRNA levels that reflect myocardial tissue state without directly sampling the tissue. This mediator approach allows indirect measurement of cardiac microRNA levels, resolving the contradiction between measurement accuracy and procedural complexity.
2Reliability
If single time point microRNA measurement is performed, then simple assessment is obtained, but temporal patterns of left ventricular remodeling cannot be detected
Solution Approach 1:
The patent establishes a predetermined multi-timepoint sampling schedule (e.g., 1, 7, 14, 28, 90 days post-MI) that is planned in advance. This preliminary action approach ensures temporal pattern detection capability while organizing the time investment systematically, resolving the contradiction between assessment reliability and time loss.
3Measurement precision
If microRNA detection is performed without normalization, then measurement process is simplified, but measurement precision and reliability are reduced
Solution Approach 1:
The patent applies normalization to transform raw microRNA measurement data into standardized values by comparing against reference genes (e.g., U6, GAPDH, β-actin) or control samples. This parameter transformation resolves the contradiction by improving measurement precision through mathematical adjustment while adding only a computational step rather than procedural complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for sensitive and reliable assessment of left ventricular remodeling and cardiac health by correlating microRNA temporal patterns with the severity of myocardial infarction and remodeling processes, providing valuable diagnostic and prognostic insights.
Implementation Method 1
The level of microRNAs can be measured in a body fluid, such as plasma and serum. Disclosed is method comprising detecting one or more target microRNAs in a body fluid of a subject
Data Source
AI summary
Disclosed are methods and materials for assessing cardiac failure, cardiac hypertrophy, and left ventricular remodeling using microRNA levels. The level of microRNAs can be measured in a body fluid, such as plasma and serum.